Edwards Beat Analysts' And Its Own Projections in Q2 As TAVR Volumes Recover

The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.

MT2007_Edwards-Commander-Valve_1200.jpg
Edwards Lifesciences' Sapien 3 transcatheter aortic valve with the Commander delivery system • Source: Edwards Lifesciences

The volume of transcatheter aortic valve replacement (TAVR) procedures performed by hospitals around the world is gradually recovering to its pre-pandemic level, according to market leader Edwards Lifesciences Corp.

In the second quarter of 2020, revenue from SAPIEN devices declined 11.5% year-over-year to $594.3m. Sales of TAVR devices were...

More from Business

More from Medtech Insight